Xenon Pharmaceuticals Inc.
Every calculator, already run for XENE
Open the full toolkit →You have the numbers on XENE. Get the argument.
A written report on which of these readings actually decide the outcome for Xenon Pharmaceuticals Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering XENEAnalyst Price Target Disagreement for Xenon Pharmaceuticals Inc.
Wall Street's bull case implies +164% from the current price; the bear case implies +25%. A 139% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for XENE
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeti…
XENE — frequently asked
Is XENE a buy right now?
Wall Street's consensus rating on Xenon Pharmaceuticals Inc. is Strong Buy across 19 analysts, with a mean price target of $74.31 (+102% vs. the current $36.72). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is XENE's next earnings date?
Xenon Pharmaceuticals Inc. is next scheduled to report earnings around Nov 2, 2026. A full XENE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Xenon Pharmaceuticals Inc.?
Analysts covering Xenon Pharmaceuticals Inc. (XENE) range from a bear-case target of $46.00 to a bull-case high of $97.00, with a mean consensus target of $74.31 across 18 analysts. The spread of $51.00 (139% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Xenon Pharmaceuticals Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Xenon Pharmaceuticals Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full XENE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Xenon Pharmaceuticals Inc., in minutes. 3 free reports included with every account — no credit card required.